Medincell

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, has entered into a partnership with France-based biopharmaceutical firm Medincell (EPA: MEDCL) to develop up to six long-acting injectable treatments across multiple therapeutic areas. As per the agreement, Medincell will receive an upfront payment of USD 35 million, with the potential for…